India Breast Cancer Drugs Roundup: Trastuzumab Prices Plunge, Enhertu Looms

 
• By Anju Ghangurde

Glenmark has dropped the price of its trastuzumab biosimilar by over 70% in India. Scrip talks to experts on what that may mean for the competition and also spotlights action around other HER2-directed therapies, including the impending arrival of blockbuster ADC Enhertu.

Price Cuts, Launch Activity On Indian Market For Cancer Drugs • Source: Shutterstock

More from India

More from Focus On Asia